$3.32 0.03 (+0.91%)
11/27/2009 12:59 PM

Trimeris, Inc. (TRMS)

CAPS Rating: 5 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors.

Results 1 - 11 of 11

Recs

0
Member Avatar 1203cc (< 20) Submitted: 7/11/2008 11:28:45 PM : Outperform Start Price: $2.97 TRMS Score: +21.63

I'm just here for the dividends

Recs

0
Member Avatar tboneuva (29.64) Submitted: 5/1/2008 10:27:04 AM : Outperform Start Price: $2.86 TRMS Score: +34.29

solid health care products company

Recs

0
Member Avatar WERDOSD44 (29.85) Submitted: 3/24/2008 4:18:36 PM : Outperform Start Price: $2.56 TRMS Score: +45.64

THIS COMPANIES PROFITS HAVE DOUBLED

Recs

0
Member Avatar djinsanity (< 20) Submitted: 2/10/2008 12:42:05 PM : Outperform Start Price: $2.68 TRMS Score: +37.98

Leader in anti-viral drug treatments, and the world will continue to fund this type of research, Leader in anti-HIV drug research.

Recs

0
Member Avatar utosweet (24.88) Submitted: 2/4/2008 6:22:54 PM : Outperform Start Price: $2.69 TRMS Score: +39.58

Something must give on this HIV desease.So,this Bio-tech Co. is one of the best @ $6.59 I'm looking for a run-up to $14.00 Buy November 2008.

Recs

0
Member Avatar gdsfgggg (58.78) Submitted: 7/4/2007 12:50:40 PM : Outperform Start Price: $2.69 TRMS Score: +47.53

Stellar cash flow. With financials like this the SP is sure to turnaround. Largely owned by institutions so watch for big price moves on the moving averages. On paper it looks golden, let's hope that translates into bags of money.

Recs

3
Member Avatar majakblue (< 20) Submitted: 5/25/2007 2:14:57 PM : Underperform Start Price: $2.86 TRMS Score: -39.73

The company appears to be relying on collaborations with big pharma, which sends me a signal that it will stay small and only marginally profitable if at all. It expects only modest growth of its product Fuzion, despite the fact that an HIV targeted drug with new or better technology should be a big winner, suggesting that perhaps the technology is over-rated, or that its deals with Roche would not yield much revenue.

Also, most of the stock is owned by large investors and they get impatient pretty quickly and will dump when there is an upturn, leaving the rest of us hanging.

Recs

0
Member Avatar lcsystem (33.96) Submitted: 4/11/2007 7:44:36 PM : Outperform Start Price: $2.81 TRMS Score: +38.11

Down on CEO departure, but solid sales and earnings, good buy opportunity.

Recs

0
Member Avatar virtualkccontra (38.27) Submitted: 1/22/2007 11:49:59 PM : Outperform Start Price: $5.30 TRMS Score: -18.59

buy

Recs

0
Member Avatar pvandevelde1965 (< 20) Submitted: 12/31/2006 5:45:41 AM : Outperform Start Price: $5.23 TRMS Score: -18.23

Surprise growth in its HIV drug.

Recs

3
Member Avatar sleepyseth (98.04) Submitted: 11/7/2006 4:10:31 PM : Outperform Start Price: $4.01 TRMS Score: -1.53

Buy this company before the earnings announcement. This will be their first quarter of steady positive earnings (actually their second positive quarter ever). The stock is down a lot over the past couple of years, but now the company is actually going to be profitable. The growth estimates look phenominal too. Hopefully the reason that the stock has gone downis not because people know something that isn't announced, but because they are just now making real money. Watch the earnings report closely, hopefully this company has bottomed.

Results 1 - 11 of 11

Featured Broker Partners